Table 2 Univariate and multivariate analysis for progression-free survival
Characteristic | Univariate | Multivariate | ||
|---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | |
Age at diagnosis | ||||
≤ 65 | 1 | 0.412 | ||
> 65 | 0.76 (0.40–1.45) | |||
Stage | ||||
I -II | 1 | 0.042 | 1 | 0.222 |
III-IV | 2.10 (1.03–4.28) | 1.59 (0.75–3.36) | ||
Histology | ||||
High-grade serous carcinoma | 1 | 0.125 | 1 | 0.757 |
Others | 0.70 (0.44–1.10) | 0.92 (0.57–1.51) | ||
ECOG performance status | ||||
0 | 1 | 0.089 | 1 | 0.790 |
≥ 1 | 1.32 (0.96–1.83) | 0.95 (0.66–1.37) | ||
CA 125 at diagnosis | ||||
≤ 200 | 1 | 0.046 | 1 | 0.581 |
> 200 | 1.40 (1.01–1.94) | 1.10 (0.78–1.56) | ||
Type of cytoreductive surgery | ||||
Primary | 1 | < 0.001 | 1 | 0.005 |
Interval | 2.02 (1.44–2.82) | 1.76 (1.18–2.62) | ||
Complete cytoreductive surgery | ||||
Yes | 1 | < 0.001 | 1 | 0.006 |
No | 2.64 (1.65–4.23) | 1.99 (1.22–3.24) | ||
Chemotherapy regimen | ||||
Conventional | 1 | 0.036 | 1 | 0.040 |
Dose-dense | 0.83 (0.69–0.99) | 0.82 (0.68–0.99) | ||
BRCA1/2 mutation | ||||
No | 1 | 0.766 | ||
Yes | 1.08 (0.66–1.82) | |||
Family history of breast or ovarian cancer | ||||
No | 1 | 0.916 | ||
Yes | 0.98 (0.70–1.38) | |||